CE for Nurses

In the past decade, the treatment landscape for multiple myeloma (MM) has significantly improved with the introduction of several novel treatment regimens. Oncology nurses are constantly challenged to stay up-to-date with these recent advances in the management of MM.


New Strategies for Multiple Myeloma Care: Case Studies for Nurses

Co-Chairs: Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN; Joseph D. Tariman, PhD, RN, ANP-BC, FAAN
Faculty: Amy E. Pierre, RN, MSN, ANP-BC; Tiffany Richards, PhD, ANP-BC, AOCNP®


New Strategies for MM Care Multiple myeloma care is rapidly evolving with new agents and combinations, new testing, and risk-adapted treatment strategies. Four highly experienced nurses will share their expertise during this 1.5 CNE symposium (3 sessions of 0.5 CNE) while using real-life patient case scenarios to focus on symptom management, infection control, and nursing implications. The participants can take part in a single session, two sessions, or the entire symposium. Free downloadable tools and resources are provided.

Available now, earn your CNE credits for these 3 activities!

New Strategies for Multiple Myeloma Care: Case Studies for Nurses – Part 1: Newly Diagnosed Multiple Myeloma
New Strategies for Multiple Myeloma Care: Case Studies for Nurses – Part 1: Newly Diagnosed Multiple Myeloma
CNE
Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN; and Joseph D. Tariman, PhD, RN, ANP-BC, FAAN
Release Date: August 18, 2020
Expiration Date: August 18, 2021
This activity on newly diagnosed multiple myeloma will include an overview of the disease, as well as current treatment workup and testing recommendations for multiple myeloma. Through the cases of June and Lisa, our faculty will explore transplant eligibility, induction, and maintenance therapy. Please remember to complete part 2 and 3 to receive a total of 1.5 CNE credits (3 sessions at 0.5 CNE). Free downloadable tools and resources are provided after completing the post-test and activity evaluation survey.

Provided by the International Myeloma Foundation

Accredited by Annenberg Center for Health Sciences at Eisenhower

Supported by educational grants from Bristol Myers Squibb (formerly Celgene); GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; Oncopeptides, Inc.; and Takeda Oncology.
Begin, Earn Credit
 
New Strategies for Multiple Myeloma Care: Case Studies for Nurses – Part 2: Relapsed Multiple Myeloma
New Strategies for Multiple Myeloma Care: Case Studies for Nurses – Part 2: Relapsed Multiple Myeloma
CNE
Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN; and Amy E. Pierre, RN, MSN, ANP-BC
Release Date: August 18, 2020
Expiration Date: August 18, 2021
This activity on relapsed multiple myeloma will include some recently approved drugs and dosage forms. Through the cases of Steve and Michelle, our faculty will review treatment considerations in the cases of early relapsed patients. Please remember to complete part 1 and 3 to receive a total of 1.5 CNE credits (3 sessions at 0.5 CNE). Free downloadable tools and resources are provided after completing the post-test and activity evaluation survey.

Provided by the International Myeloma Foundation

Accredited by Annenberg Center for Health Sciences at Eisenhower

Supported by educational grants from Bristol Myers Squibb (formerly Celgene); GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; Oncopeptides, Inc.; and Takeda Oncology.
Begin, Earn Credit
 
New Strategies for Multiple Myeloma Care: Case Studies for Nurses – Part 3: Heavily Pretreated Multiple Myeloma and Drugs in Development
New Strategies for Multiple Myeloma Care: Case Studies for Nurses – Part 3: Heavily Pretreated Multiple Myeloma and Drugs in Development
CNE
Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN; and Tiffany Richards, PhD, ANP-BC, AOCNP®
Release Date: August 18, 2020
Expiration Date: August 18, 2021
This activity will focus on heavily pretreated multiple myeloma and drugs in development. Through the case of Carl, a patient who has received several multiple myeloma therapies over his 10-year history with the disease, our faculty will discuss clinical trial participation, and drugs in development. Please remember to complete part 1 and 2 to receive a total of 1.5 CNE credits (3 sessions at 0.5 CNE). Free downloadable tools and resources are provided after completing the post-test and activity evaluation survey.

Provided by the International Myeloma Foundation

Accredited by Annenberg Center for Health Sciences at Eisenhower

Supported by educational grants from Bristol Myers Squibb (formerly Celgene); GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; Oncopeptides, Inc.; and Takeda Oncology.
Begin, Earn Credit